全文获取类型
收费全文 | 101篇 |
免费 | 4篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 10篇 |
临床医学 | 6篇 |
内科学 | 61篇 |
皮肤病学 | 1篇 |
外科学 | 9篇 |
预防医学 | 7篇 |
药学 | 9篇 |
出版年
2021年 | 3篇 |
2020年 | 1篇 |
2018年 | 5篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 3篇 |
2013年 | 9篇 |
2012年 | 11篇 |
2011年 | 12篇 |
2010年 | 4篇 |
2009年 | 6篇 |
2008年 | 4篇 |
2007年 | 7篇 |
2006年 | 5篇 |
2005年 | 4篇 |
2004年 | 8篇 |
2003年 | 4篇 |
2002年 | 4篇 |
2001年 | 5篇 |
2000年 | 4篇 |
1989年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有105条查询结果,搜索用时 0 毫秒
101.
102.
Schwertfeger E Wehrens J Oberhauser V Katzenwadel A Rump LC 《Journal of autonomic pharmacology》2001,21(4):205-210
1. We tested the vasoactive properties of the immunosuppressive drug FK 506 (tacrolimus) in preconstricted rat and human isolated renal arteries in vitro. 2. In rat renal arteries, tacrolimus (3, 10 microM) showed a direct and dose-dependent contractile effect by maximally 23 microm (10% of the noradrenaline effect), which was only observed in the presence of intact endothelium. Moreover, a lower concentration of tacrolimus (1 microM) potentiated pressor responses to the sympathetic neurotransmitter noradrenaline but not to ATP in this species. ATP- (0.01-10 microM) induced vasodilation was not affected by tacrolimus (1 microM). 3. In contrast, in human interlobar arteries, tacrolimus failed to induce direct vasoconstriction and did not significantly potentiate constrictor responses to noradrenaline. Acetylcholine-(1 microM) induced vasodilation was much smaller in human than in rat renal arteries suggesting the lack of functional endothelium in the human preparation. 4. The findings suggest that tacrolimus releases an endothelium-derived constricting factor in rat renal arteries to increase vascular tone and to potentiate pressor responses to noradrenaline. In human interlobar arteries, this effect of tacrolimus is not observed probably because of the absence of functional endothelium or the necessary mediator mechanism. 相似文献
103.
104.
105.
Ryanodine receptor (RyR2) dysfunction, which may result from a variety of mechanisms, has been implicated in the pathogenesis of cardiac arrhythmias and heart failure. In this review, we discuss the important role of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) in the regulation of RyR2-mediated Ca(2+) release. In particular, we examine how pathological activation of CaMKII can lead to an increased risk of sudden arrhythmic death. Finally, we discuss how reduction of CaMKII-mediated RyR2 hyperactivity might reduce the risk of arrhythmias and may serve as a rationale for future pharmacotherapeutic approaches. 相似文献